In this article, we focus on the supply chain and how players ... half-life and manufacturing centralisation (see Figure 2): •Lu-177 (half-life approximately 6.7 days), a beta-emitting isotope ...

The supply chain for this radioisotope has been particularly ... Terbium-161 is similar to Lutetium-177 in its half-life and decay processes, which include β ̄-particles and γ-ray emission with ...

Under the terms of the agreement, Radiopharm will use ITM's n.c.a. 177 Lu across its clinical pipeline, including in key programs such as RAD 204 (PD-L1-targeting nanobody, Phase 1), RAD 202 ...

Under the terms of the agreement, Radiopharm will use ITM’s n.c.a. 177 Lu across its clinical pipeline, including in key programs such as RAD 204 (PD-L1-targeting nanobody, Phase 1), RAD 202 ...

non-carrier-added Lutetium-177 (n.c.a. 177Lu), to enable its usage in the clinical and potential future commercial development of the 177Lu-based molecules in Radiopharm’s development pipeline.

“Lutetium-177 is required for three of our more advanced assets and this supply agreement with a radiopharmaceutical leader like ITM is another important step to ensure quality, reliability, and ...

Radiopharm secures lutetium-177 supply agreement View all comments (0) 0 Latest comments Post Comment Guidelines Trade With A Regulated Broker Indices Commodities Bonds Stocks PSEi Composite ...